EFFICACY OF TREATMENT WITH ORLISTAT IN THE TREATMENT OF OBESITY AGAINST THE BACKGROUND OF METABOLIC SYNDROME

Abstract

The article provides information on a study conducted to clarify the effectiveness of orlistat treatment of obesity against the background of metabolic syndrome (MS).
The study included 257 MS patients aged 30-60 who were treated at Sheki Central District Hospital and "Alyans" clinics. The effectiveness of monotherapy and combined treatment with xenical drug and lifestyle modification (LM) therapy in MS patients was studied. In the treatment of obesity in the setting of MS, a reduction of 5% to 10% of body weight was observed in 56.1% to 60.2% of patients, and a weight loss of >10% was observed in 25.2% to 28.4% of patients treated with orlistat. Combined therapy with orlistat and LM leads to reduction of CVD risk factors and an improvement in quality of life in most patients with MS and DM2.